Celltrion, Foreign Investors Net Buy 328,944 Shares in Last 5 Days... Stock Price 331,500 KRW (-0.9%)

As of 11:31 AM on the 29th, Celltrion is trading at 331,500 KRW, down 0.9% from the previous day. The trading volume is 390,339 shares, which is about 26.54% of the previous day's volume. Celltrion is known as a manufacturer of protein and biopharmaceutical products.

On January 28, Minjeong Seon, a researcher at Hana Financial Investment, stated, "After the announcement of the Phase 2 clinical trial results for the COVID-19 antibody treatment Regkirona, Celltrion's stock price is currently uncertain due to 1) whether Regkirona will enter the U.S. market, and 2) the expansion of sales for Remsima SC. Therefore, the stock price may remain range-bound for the time being. Given the nature of the biosimilar business, growth can be expected through the annual launch of new products. This year, new products are scheduled to be launched sequentially, including Uplyma, a Humira biosimilar newly introduced in Europe." He set Celltrion's target price at 364,000 KRW.

Over the past five days, individual investors have net sold 183,896 shares of Celltrion, while foreigners and institutions have net bought 328,944 shares and net sold 145,546 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.